Ascendis Pharma A/S ASND
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 100th percentile, 5-year average -14.4x
#2366 of 2996 stocks by PE (1 = cheapest)
Above its usual level · 71st percentile, 5-year average -19.2x
#4998 of 5338 stocks by PB (1 = cheapest)
Near the bottom of its 5-year range · 0th percentile, 5-year average 181.9x
#4638 of 5161 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 10.07 | – | -19.16 | 71% (pricier than usual) | #4998 of 5338 (1 = cheapest) |
| PE | 34.65 | 26.46 | -14.43 | 100% (pricier than usual) | #2366 of 2996 (1 = cheapest) |
| PS | 12.61 | 7.96 | 181.90 | 0% (cheaper than usual) | #4638 of 5161 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on ASND.
Sign in to join the discussion.